IPO registrations (S-1, F-1) · Registrants
INVIVO THERAPEUTICS HOLDINGS CORP.
- SEC CIK
- 1292519 · filings on EDGAR ↗
- Former names
- Design Source, Inc. (2004–2010)
- Registration
- Form S-1, first filed 2011-02-01, last 2022-11-09; 8 initial registrations, 9 amendments
- Outcome
- Final prospectus filed 2018-06-22; declared effective 2011-07-29
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- NV
- Business address
- ONE KENDALL SQUARE, BUILDING 1400 EAST 4TH FLOOR, Cambridge, MA 02139
- EDGAR entity type
- operating
- Insiders and CEO pay
- INVIVO THERAPEUTICS HOLDINGS CORP. on the corporate pages
Offering terms
- Final price
- $2.00 per share (424B4 filed 2018-06-22)
- Shares sold
- 388,403
- Gross proceeds
- $776,806 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NVIV
- Lead underwriters
- Ladenburg Thalmann
- Syndicate
- Series A Warrant; Warrant and
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: INVIVO THERAPEUTICS HOLDINGS CORP. EXACT (CIK (EXACT))
- SEC filer: Design Source, Inc. EXACT (CIK (EXACT))
- Person page: Adam K Stern Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Richard M Toselli Md Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 39
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2011-02-01 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001193125-11-020271 ↗ |
| 2011-05-19 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001193125-11-145252 ↗ |
| 2011-06-09 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001193125-11-161974 ↗ |
| 2011-06-30 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001193125-11-178842 ↗ |
| 2011-07-19 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001193125-11-190971 ↗ |
| 2011-07-29 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-11-002328 ↗ |
| 2011-12-16 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001193125-11-344083 ↗ |
| 2012-01-19 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-12-000228 ↗ |
| 2012-04-23 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-12-001127 ↗ |
| 2013-05-22 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-13-001617 ↗ |
| 2015-02-10 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-15-000367 ↗ |
| 2016-06-17 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-16-004943 ↗ |
| 2016-06-17 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-16-004944 ↗ |
| 2016-06-17 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-16-004945 ↗ |
| 2018-01-29 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-004326 ↗ |
| 2018-02-09 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-008065 ↗ |
| 2018-02-12 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-18-000415 ↗ |
| 2018-04-24 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-026229 ↗ |
| 2018-06-14 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-040189 ↗ |
| 2018-06-20 | S-1MEF | S-1MEF (added securities) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-041380 ↗ |
| 2018-06-20 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-18-001553 ↗ |
| 2018-06-22 | 424B4 | 424B4 (final prospectus) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-041756 ↗ |
| 2018-06-26 | 424B4 | 424B4 (final prospectus) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-18-042287 ↗ |
| 2019-05-28 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-19-001218 ↗ |
| 2019-06-28 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-19-001468 ↗ |
| 2019-11-14 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-19-002574 ↗ |
| 2020-02-21 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001047469-20-000997 ↗ |
| 2020-03-02 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001047469-20-001151 ↗ |
| 2020-03-05 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001047469-20-001217 ↗ |
| 2020-03-06 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-20-000479 ↗ |
| 2020-03-09 | 424B4 | 424B4 (final prospectus) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001047469-20-001325 ↗ |
| 2020-05-22 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001047469-20-003187 ↗ |
| 2020-06-04 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-20-001343 ↗ |
| 2020-10-07 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-20-112754 ↗ |
| 2020-10-16 | S-1/A | S-1/A (amendment) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-20-115633 ↗ |
| 2020-10-22 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-20-002952 ↗ |
| 2020-10-26 | 424B4 | 424B4 (final prospectus) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-20-117863 ↗ |
| 2022-11-09 | S-1 | S-1 (registration) | INVIVO THERAPEUTICS HOLDINGS CORP. | 0001104659-22-116043 ↗ |
| 2022-11-21 | EFFECT | EFFECT (declared effective) | INVIVO THERAPEUTICS HOLDINGS CORP. | 9999999995-22-003362 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-06-14 | S-1/A | registration statement | 1,486,486 | - | Nasdaq NVIV | 3 | primary document; shares headline, cover names 3 | document ↗ | ||
| 2018-06-22 | 424B4 | final prospectus | $2.00 | 388,403 | $776,806 | Nasdaq NVIV | 3 | primary document; price sentence, shares headline, proceeds computed, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Coker Peter L | Director,Officer | Secretary | 1 | 2006 | |
| Reichard Peter A | Director,Officer | President, CEO | 1 | 2006 | |
| Coker Peter L. | Director,Officer,TenPercentOwner | Secretary | 1 | 2009 | |
| Reichard Peter | Director,Officer,TenPercentOwner | Chief Executive Officer | 2 | 2009 | |
| LANGER ROBERT | TenPercentOwner | 16 | 2010–2013 | ||
| NOLEN GEORGE | Director | 4 | 2010–2013 | ||
| PEDRA CHRISTI | Director | 3 | 2010–2011 | ||
| REYNOLDS FRANCIS | Director,Officer,TenPercentOwner; TenPercentOwner | CEO, CFO; Chief Executive Officer | 147 | 2010–2014 | |
| ROBERTS RICHARD JOHN | Director | 17 | 2010–2022 | ||
| KIMBERLIN KEVIN | TenPercentOwner | 2 | 2010 | ||
| STERN ADAM K | Director | 5 | 2010–2012 | person page Fuzzy | |
| Wirth Edward | Officer | Chief Science Officer | 2 | 2011 | |
| HESS BRIAN | Officer | CHIEF SCIENCE OFFICER; Chief Technology Officer | 3 | 2012–2013 | |
| DiPietro Kenneth | Director | 8 | 2012–2018 | ||
| MCCARTHY JOHN A JR | Director | 6 | 2013–2015 | ||
| ASTRUE MICHAEL J | Officer | Interim CEO; INTERIM CEO | 2 | 2013–2014 | |
| Moran Sean F. | Officer | Acting Chief Financial Officer | 4 | 2013 | |
| PERRY GREGORY D | Officer | Interim CFO | 2 | 2013–2014 | |
| MCALLISTER STEVEN F | Officer | Chief Financial Officer; INTERIM CFO | 5 | 2014–2016 | |
| PERRIN MARK D | Director,Officer | CHIEF EXECUTIVE OFFICER | 6 | 2014–2017 | |
| JOSEPH TAMARA L | Officer | SVP, General Counsel | 7 | 2014–2017 | |
| Ulich Thomas R | Officer | Chief Scientific Officer | 6 | 2014–2017 | |
| MARSHAK DANIEL R | Director | 8 | 2014–2022 | ||
| MERRIFIELD C ANN | Director | 10 | 2014–2022 | ||
| Lorianne Masuoka K. | Officer | Chief Medical Officer | 4 | 2015–2016 | |
| Morrison Christina | Director | 6 | 2016–2022 | ||
| STAHL PAMELA J | Officer | Chief Commercial Officer | 3 | 2016–2017 | |
| Hatfield Jeffrey S. | Director | 3 | 2016–2018 | ||
| Golarz Melanie | Officer | Interim CFO | 1 | 2017 | |
| McNulty Christopher | Officer | Chief Financial Officer | 2 | 2017 | |
| Toselli Richard M. | Director,Officer; Officer | CEO and CMO; Chief Medical Officer; See Remarks | 19 | 2017–2022 | person page Fuzzy |
| Modestino Jeffrey | Officer | See Remarks | 1 | 2018 | |
| CHRISTOPHER RICHARD | Officer | CFO and Treasurer; Chief Financial Officer | 6 | 2019–2022 | |
| ROSENTHAL BOB | Director | 3 | 2021–2022 | ||
| Hamel Heather | Officer | Chief Legal Officer and GC | 2 | 2022 | |
| Foose Brice | TenPercentOwner | 3 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-10-14 | INVIVO THERAPEUTICS HOLDINGS CORP. | Biotechnology | $6,249,999 | $6,249,999 | 1 | 1 |
| 2020-04-28 | INVIVO THERAPEUTICS HOLDINGS CORP. | Biotechnology | $3,022,576 | $3,022,576 | 8 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | INVIVO THERAPEUTICS HOLDINGS CORP. | MA | Form D private offerings | CIK (EXACT) |
| SEC filer | INVIVO THERAPEUTICS HOLDINGS CORP. | SEC filers (EDGAR) | CIK (EXACT) | |
| Person page | Adam K Stern | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Richard M Toselli Md | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, MA first:
- NMT MEDICAL INC MA
- ARBIOS SYSTEMS INC MA
- INSULET CORP MA
- LEMAITRE VASCULAR INC MA
- BIOVENTRIX, INC. MA
- NeuroMetrix, Inc. MA
- ACCELLENT LLC MA
- Lyra Therapeutics, Inc. MA
- T2 Biosystems, Inc. MA
- Corindus Vascular Robotics, Inc. MA
In other datasets, the same topic (Technology) in MA:
- Form D issuer: 10 Percent Happier, Inc. (Form D private offerings)
- Lobbying client: 5G ACTION NOW (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology